The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | CAR-T as a next-generation therapy for CLL
Marco Ruella, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, shares some important points from his presentation at ESH CLL 2022, which focuses on the future use of chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of chronic lymphocytic leukemia (CLL). Although CAR-T products have not yet been approved for CLL treatment, Dr Ruella discusses the potential future use of CD19-directed CAR-T in CLL, as well as the current use of Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. To conclude, Dr Ruella briefly discusses how resistance of CLL cells to CARs may be overcome, and the importance of conducting more research in this area. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
